When Do Tysabri PML Symptoms Appear? A Timeline Based on the FDA Label

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Occupational Exposure

If you or a loved one is taking Tysabri, you may wonder when symptoms of Progressive Multifocal Leukoencephalopathy (PML) could first appear. The FDA label provides a clear timeline: most cases occur after two years of treatment, though earlier onset is possible. This understanding builds on decades of pharmacovigilance research that has shaped how we monitor for rare but serious drug side effects. This page outlines the symptom timeline and key documentation points from the official label.

Medical Background and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri exposure, understanding the medical evidence and legal considerations—including the statute of limitations for filing a claim—is essential. PML is an opportunistic viral infection of the brain caused by the JC virus that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri increases the risk of PML, and the prescribing information includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, and physicians must weigh expected benefit against the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis

PML presents with progressive neurological deficits, including cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis is typically confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. The onset of symptoms can occur months to years after starting Tysabri, and the infection often progresses rapidly. The prescribing information instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite such monitoring, PML can still develop, and outcomes are frequently poor.

Mechanistic Pathways Linking Tysabri to PML

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking lymphocyte adhesion and migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing reactivation of latent JC virus in the brain. The resulting lytic infection of oligodendrocytes leads to demyelination and the characteristic lesions of PML. The risk is highest in patients with anti-JCV antibodies, as these indicate prior exposure to the virus. The duration of therapy amplifies this risk, with longer exposure increasing the probability of viral reactivation.

Adequacy of Warnings and Settlement Considerations

The boxed warning on Tysabri's label explicitly states the increased risk of PML and identifies the three key risk factors. However, the adequacy of these warnings has been questioned in legal contexts. Some patients and their families argue that the risks were not sufficiently communicated to prescribers or patients, particularly regarding the magnitude of risk and the need for regular monitoring. The label also mandates enrollment in the TOUCH Prescribing Program, a restricted distribution program designed to ensure patients understand the risks and undergo regular monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML cases have continued to occur, leading to litigation. For Illinois residents who have developed PML after Tysabri use, settlement options may be available through mass tort litigation or individual claims. The statute of limitations for personal injury claims in Illinois is generally two years from the date the injury was discovered or should have been discovered. For PML, this date is often when a definitive diagnosis is made. Given the latency between Tysabri exposure and PML onset, careful documentation of the timeline is critical. Patients should gather medical records, including dates of Tysabri infusions, dates of symptom onset, and diagnostic test results. Settlement amounts can vary based on factors such as severity of disability, medical expenses, lost income, and pain and suffering. Legal counsel experienced in pharmaceutical litigation can help assess the strength of a claim and negotiate a settlement.

Timeline Between Exposure and Documented Harm

The risk of PML increases with longer Tysabri treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported after shorter exposure, especially in patients with additional risk factors. The onset of PML symptoms can be insidious, and diagnosis may be delayed. For statute of limitations purposes, the clock typically starts when the patient or a reasonable person would have discovered the link between Tysabri and the injury. This may be at the time of PML diagnosis or when symptoms first appear. Given the complexity, affected individuals should seek legal advice promptly to avoid missing the filing deadline.

Conclusion

Tysabri-associated PML is a devastating condition with high morbidity and mortality. The medical evidence clearly establishes the drug's role in increasing PML risk, and the label provides warnings and risk mitigation strategies. For Illinois patients, the statute of limitations for filing a claim is generally two years from discovery of the injury. Settlement considerations depend on individual circumstances, including the severity of harm and the adequacy of warnings provided. Patients and families should consult with legal and medical professionals to navigate the complexities of a potential claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Illinois?

In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For Tysabri-related PML, this typically starts when a definitive diagnosis is made or when symptoms first appear. It is crucial to seek legal advice promptly to avoid missing the deadline.

What are the risk factors for developing PML while on Tysabri?

Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.